Engineered immune cells take aim at childhood cancers

NCT ID NCT07148050

Recruiting now Disease control Sponsor: Seattle Children's Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests a new type of immunotherapy for children and young adults with solid tumors that have not responded to standard treatments. The therapy uses the patient's own immune cells, which are genetically modified in the lab to recognize and attack cancer cells that carry a protein called GPC3. The main goals are to see if the treatment is safe and can be made successfully for each patient.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: genetically modified immune cells (CAR T cells) that target a protein called GPC3 on tumor cells
What this could lead to: If successful, this could point toward a new treatment option for children with hard-to-treat solid tumors that have come back after standard therapy.
What could go wrong: This is a very early Phase 1 trial with only 21 participants, so it is primarily testing safety. The treatment may not shrink tumors, and there are risks of serious side effects like cytokine release syndrome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EMBRYONAL SARCOMA OF LIVER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Endodermal Sinus Tumor hepatoblastoma hepatocellular carcinoma liposarcoma Liver Neoplasms neoplasm rhabdoid tumor rhabdomyosarcoma undifferentiated embryonal sarcoma of the liver Wilms tumor yolk sac tumor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EMBRYONAL SARCOMA OF LIVER HEPATOBLASTOMA HEPATOCELLULAR CARCINOMA LIPOSARCOMA LIVER CELL CARCINOMA MALIGNANT RHABDOID TUMOR RHABDOMYOSARCOMA SOLID TUMOR (EXCLUDING CNS) WILMS TUMOR YOLK SAC TUMOR

Contacts and locations

Locations

Seattle Children's Hospital
RECRUITING

Seattle, Washington, 98105, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.